Bridges Investment Management Inc. Purchases Shares of 961 Danaher Co. (NYSE:DHR)

Bridges Investment Management Inc. acquired a new position in shares of Danaher Co. (NYSE:DHR) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 961 shares of the conglomerate’s stock, valued at approximately $240,000.

A number of other hedge funds and other institutional investors have also made changes to their positions in the stock. Cape Investment Advisory Inc. acquired a new stake in shares of Danaher in the 4th quarter valued at about $25,000. Tsfg LLC grew its holdings in shares of Danaher by 733.3% during the first quarter. Tsfg LLC now owns 100 shares of the conglomerate’s stock worth $25,000 after buying an additional 88 shares in the last quarter. CarsonAllaria Wealth Management Ltd. acquired a new stake in Danaher in the 2nd quarter valued at approximately $25,000. nVerses Capital LLC bought a new stake in Danaher in the 2nd quarter valued at approximately $25,000. Finally, Redmont Wealth Advisors LLC acquired a new position in Danaher during the 1st quarter worth approximately $30,000. 79.05% of the stock is currently owned by institutional investors and hedge funds.

Danaher Trading Down 1.4 %

Shares of DHR stock opened at $272.63 on Monday. Danaher Co. has a 12-month low of $182.09 and a 12-month high of $281.70. The company has a market capitalization of $201.93 billion, a PE ratio of 46.21, a price-to-earnings-growth ratio of 4.48 and a beta of 0.83. The firm has a 50 day moving average price of $267.62 and a two-hundred day moving average price of $257.19. The company has a quick ratio of 1.04, a current ratio of 1.43 and a debt-to-equity ratio of 0.33.

Danaher (NYSE:DHR) last released its quarterly earnings results on Tuesday, July 23rd. The conglomerate reported $1.72 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.57 by $0.15. The business had revenue of $5.74 billion during the quarter, compared to the consensus estimate of $5.59 billion. Danaher had a return on equity of 11.06% and a net margin of 16.94%. The firm’s quarterly revenue was down 2.9% on a year-over-year basis. During the same period in the previous year, the company posted $2.05 EPS. As a group, analysts predict that Danaher Co. will post 7.59 earnings per share for the current year.

Danaher Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 25th. Shareholders of record on Friday, September 27th will be issued a $0.27 dividend. This represents a $1.08 dividend on an annualized basis and a yield of 0.40%. The ex-dividend date of this dividend is Friday, September 27th. Danaher’s dividend payout ratio is currently 18.31%.

Insiders Place Their Bets

In related news, SVP Georgeann Couchara sold 952 shares of the business’s stock in a transaction that occurred on Monday, August 26th. The stock was sold at an average price of $268.37, for a total value of $255,488.24. Following the completion of the sale, the senior vice president now directly owns 4,212 shares in the company, valued at $1,130,374.44. The sale was disclosed in a filing with the SEC, which is available at this link. In other news, CEO Rainer Blair sold 9,007 shares of the business’s stock in a transaction that occurred on Wednesday, July 31st. The shares were sold at an average price of $280.00, for a total value of $2,521,960.00. Following the completion of the transaction, the chief executive officer now directly owns 97,983 shares in the company, valued at approximately $27,435,240. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, SVP Georgeann Couchara sold 952 shares of the stock in a transaction that occurred on Monday, August 26th. The stock was sold at an average price of $268.37, for a total transaction of $255,488.24. Following the sale, the senior vice president now owns 4,212 shares in the company, valued at approximately $1,130,374.44. The disclosure for this sale can be found here. Insiders have sold a total of 39,659 shares of company stock worth $11,042,433 in the last quarter. Corporate insiders own 11.10% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have recently commented on DHR shares. Barclays boosted their price objective on shares of Danaher from $270.00 to $285.00 and gave the stock an “equal weight” rating in a research report on Wednesday, July 24th. Evercore ISI decreased their price objective on Danaher from $266.00 to $260.00 and set an “outperform” rating for the company in a report on Tuesday, July 2nd. The Goldman Sachs Group upped their target price on Danaher from $225.00 to $250.00 and gave the stock a “neutral” rating in a report on Wednesday, July 24th. Robert W. Baird raised their price target on Danaher from $271.00 to $278.00 and gave the company an “outperform” rating in a research note on Wednesday, July 24th. Finally, Stifel Nicolaus upped their price objective on Danaher from $235.00 to $250.00 and gave the stock a “hold” rating in a research note on Wednesday, July 24th. Seven analysts have rated the stock with a hold rating and eleven have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $278.94.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.